Understanding how IGFBP3 affects resistance to Olaparib in advanced prostate cancer
Novel roles of IGFBP3 in Olaparib resistance in advanced prostate cancer
['FUNDING_OTHER'] · VA NORTHERN CALIFORNIA HEALTH CARE SYS · NIH-11034085
This study is looking at how a protein called IGFBP3 affects advanced prostate cancer's ability to resist a treatment called Olaparib, with the goal of finding better ways to help patients respond to this therapy.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VA NORTHERN CALIFORNIA HEALTH CARE SYS (nih funded) |
| Locations | 1 site (MATHER, UNITED STATES) |
| Trial ID | NIH-11034085 on ClinicalTrials.gov |
What this research studies
This research investigates the role of IGFBP3 in the resistance of advanced prostate cancer to a treatment called Olaparib, which targets cancer cells with DNA damage repair defects. The study uses advanced cell lines that have developed resistance to Olaparib to explore how IGFBP3 influences cancer cell survival and response to treatment. By analyzing changes in gene expression and cellular behavior, the research aims to identify potential new strategies to overcome resistance and improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer who have shown resistance to Olaparib or similar PARP inhibitors.
Not a fit: Patients with early-stage prostate cancer or those who have not been treated with Olaparib may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer who are resistant to current therapies.
How similar studies have performed: Other research has shown promising results in targeting resistance mechanisms in cancer therapies, suggesting that this approach could yield significant insights.
Where this research is happening
MATHER, UNITED STATES
- VA NORTHERN CALIFORNIA HEALTH CARE SYS — MATHER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GAO, ALLEN C. — VA NORTHERN CALIFORNIA HEALTH CARE SYS
- Study coordinator: GAO, ALLEN C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced prostate cancer